Niraparib promoted long-term progression-free survival benefit in Phase 3 advanced ovarian cancer study 

Brentford, UK–headquartered GSK (LSE/NYSE:GSK) reported long-term data from the phase 3 PRIMA study indicating that the PARP inhibitor Zejula (niraparib) promoted a sustained and clinically meaningful progression-free survival (PFS) benefit in ovarian cancer patients.

The survival benefit was evident across biomarker subgroups, including BRCAm, HRd and HRp.

Patients in the HRd subgroup had a 48% reduction of progression or death compared to placebo.

The estimated probability of no progressive disease or death at four years in the broader population was 24% for niraparib compared to 14% for placebo.

GSK plans to present the updated efficacy analysis data on September 11 at the (European Society for Medical Oncology) ESMO Annual Meeting in Paris.

GSK noted in a news release that the overall survival data are “not yet mature based on the prespecified analysis plan.”

The study tested niraparib as maintenance therapy in first-line ovarian…

Read more
  • 0

‘Itty bitty’ falloposcope imaging device used inside fallopian tubes for the first time

University of Arizona BIO5 Institute Director Jennifer Barton developed the high-resolution falloposcope. [Photo courtesy of the University of Arizona]

After years of development, University of Arizona researchers have captured their first images inside fallopian tubes with a new device that could be used to search for early signs of ovarian cancer before it spreads.

University of Arizona BIO5 Institute Director Jennifer Barton developed the high-resolution falloposcope, which has a diameter of only 0.8 mm.

“It’s itty bitty,” she said in a news release. “You just couldn’t have fabricated something like this, even six, seven years ago.”

Dr. John Heusinkveld has used the falloposcope since September to look inside the fallopian tubes of four volunteers who were having their tubes removed for non-cancer reasons.

“This is the first endoscope that can fi…

Read more
  • 0

Q&A: Why IMV’s DPX-Survivac shows promise in treating ovarian cancer

The biopharmaceutical company IMV (NSDQ:IMV) has recently revealed promising data related to its lead immunotherapy as a potential ovarian cancer treatment. In the Phase 2 DeCidE1 trial, the immunotherapy DPX-Survivac with intermittent low-dose cyclophosphamide showed durable anti-tumor activity in patients with recurrent, advanced ovarian cancer.

To learn more about DPX-Survivac’s potential, we reached out to IMV Chief Medical Officer Joanne Schindler. In the following interview, Schindler touches on the standard of care for treating recurrent ovarian cancer and provides an overview of the potential of the T-cell immunotherapy for treating a range of cancers.

Could you highlight some of the main challenges in treating recurrent ovarian cancer? 

Schindler: In recurrent ovarian cancer, platinum-based chemotherapy is the standard of care option for patients who have responded to prior platinum therapy and for whom recurrence was not rapid (e.g., >…

Read more
  • 0